Trial Profile
The Efficacy Study of Aclasta (Zoledronic Acid 5mg) on Prosthetic Fixation in Postmenopausal Women After Cementless Total Hip Arthroplasty (THA): a 24 Months, Single Center, Open- Label, Randomized, Parallel Controlled Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2019
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 12 Sep 2019 Planned initiation date changed from 1 Feb 2015 to 30 Jul 2015.
- 12 Sep 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 02 Feb 2016 Planned End Date changed from 1 Aug 2019 to 1 Jan 2020 as reported by ClinicalTrials.gov record.